Bioline RX

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which focuses on oncology. Its pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is a immunotherapy treatment used fro multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.

The stock price of BioLineRx (NASDAQ: BLRX) increased from $4.88 to $5.18 (up 6.15%) pre-market. This is why it happened.

BLRX Stock: From $4.88 To $5.18 (6.15% Increase) Pre-Market Explanation

Chemocentryx

Cocrystal Pharma

Cocrystal Pharma, Inc. (NASDAQ: COCP), ChemoCentryx, Inc. (NASDAQ: CCXI), Neuronetics, Inc. (NASDAQ: STIM) and BioLineRx Ltd. (NASDAQ: BLRX) are among the biggest health care movers Tuesday.

Why Cocrystal Pharma, Chemocentryx, Neuronetics And BioLineRx Are Moving Today

Shares of BioLine RX Ltd. rocketed 60% toward a 2-year high in very active trading Tuesday, enough to pace all of the premarket gainers, after the biopharmaceutical company announced positive results from a Phase 3 trial of its treatment for multiple myeloma patients.

BioLine RX rockets on heavy volume after 'strikingly positive' trial data on cancer treatment

BioLineRx (NASDAQ: BLRX) has announced positive top-line results from GENESIS Phase 3 trial evaluating its lead clinical candidate, Motixafortide, combined with granulocyte colony-stimulating factor (G-CSF), for hematopoietic stem-cell mobilization for autologous bone marrow transplantation in multiple myeloma patients. An analysis of data on all 122 enrolled patients found highly statistically significant evidence across all primary and secondary endpoints favoring Motixafortide in addition to G-CSF, as compared to placebo plus G-CSF.

BioLineRx Stock Is Trading Higher As Motixafortide-G-CSF Combo Shows Promise In Transplant Setting For Multiple Myeloma Patients

The stock price of BioLineRx (NASDAQ: BLRX) increased from $3.19 to $5.07 (58.93% increase) pre-market. This is why it happened.

BLRX Stock: From $3.19 To $5.07 (58.93% Increase) Pre-Market Explanation

TEL AVIV, Israel, May 4, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced positive top-line results from the Company's GENESIS Phase 3 trial evaluating its lead clinical candidate, Motixafortide, in combination with granulocyte colony stimulating factor (G-CSF, the standard of care in this indication), for hematopoietic stem-cell mobilization for autologous bone marrow transplantation in multiple myeloma patients.

BioLineRx Announces Positive Top-Line Results from GENESIS Phase 3 Trial of Motixafortide in Stem-Cell Mobilization for Autologous Bone Marrow Transplantation in Multiple Myeloma Patients

Aptinyx Inc

Cyclerion Therapeutics Inc

Lineage Cell Therapeutics Inc

Palatin Technologies

5 Penny Stocks To Watch For The Last Week Of April 2021 The post Best Penny Stocks To Buy Now? 5 For Your Watch List Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks To Buy Now? 5 For Your Watch List Next Week

TEL AVIV, Israel, April 15, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical Company focused on oncology, today announced that the Company has presented a poster at the AACR Annual Meeting, which is being held April 10-15 on a virtual basis.

BioLineRx Announces Presentation at 2021 American Association for Cancer Research (AACR) Annual Meeting

BioLineRx Ltd. (BLRX) CEO Phil Serlin on Q4 2020 Results - Earnings Call Transcript

TEL AVIV, Israel, Feb. 23, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the year ended December 31, 2020 and provides a corporate update. Significant events and...

BioLineRx Reports Year-End 2020 Financial Results and Provides Corporate Update

BioLineRx Ltd. is a late-stage biopharmaceutical company focused on oncology with 2 multi-indication candidates (Phase 3 and Phase 1/2a) and 1 approved product. BioLineRx's pipeline and products consist of one "off-strategy" legacy commercialized Class 2a medical device (BL-5010 for skin lesions) and two clinical-stage therapeutics run as combination therapies, Motixafortide (BL-8040) and AGI-134.

BioLineRx: Investors Are About To Cash In On Motixafortide's Phase 3 Results

TEL AVIV, Israel, Jan. 22, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced the closing of its previously announced underwritten offering of 14,375,000 American Depositary Shares (ADSs) of...

BioLineRx Announces Closing of $34.5 Million Bought Deal Offering and Full Exercise of the Option of the Underwriter

The stock price of BioLineRx (NASDAQ: BLRX) is trading over 20% lower pre-market today. This is why it happened.

BLRX Stock Price Falls Over 20% Pre-Market: Why It Happened

TEL AVIV, Israel, Jan. 20, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that due to demand, the underwriter has agreed to increase the size of the previously announced offering and...

BioLineRx Increases Previously Announced Bought Deal Offering to $30 Million

TEL AVIV, Israel, Jan. 19, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter...

BioLineRx Announces $10 Million Bought Deal Offering

Esperion Therapeutics

Heat Biologics

Esperion Therapeutics (NASDAQ: ESPR) shares are trading higher on Wednesday after the company announced Swiss Approval for the first-in-class cholesterol-lowering treatment NILEMDO and its Combination with NUSTENDI. Esprit Holdings is an international fashion brand whose operations include Retail, Wholesale and Licensing.

Why BioLine, Esperion And More Are Moving Today

TEL AVIV, Israel, Dec. 16, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical Company focused on oncology, today announced results from the triple combination arm of the Company's COMBAT/KEYNOTE-202 clinical study evaluating...

BioLineRx Announces Final Results from Phase 2a COMBAT/KEYNOTE-202 Triple Combination Study of Motixafortide in Second Line Metastatic Pancreatic Cancer (PDAC)

BioLineRx's (BLRX) CEO Phil Serlin on Q3 2020 Results - Earnings Call Transcript

TEL AVIV, Israel, Nov. 23, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the quarter ended September 30, 2020 and provides a corporate update. Significant events...

BioLineRx Reports Third Quarter 2020 Financial Results and Provides Corporate Update

BLRX stock is blasting off on Friday morning after the company reported strong results from a Phase-3 trial for one of its cancer treatments. The post BioLineRX News: Why BLRX Stock Is Skyrocketing Today appeared first on InvestorPlace.

BioLineRX News: Why BLRX Stock Is Skyrocketing Today

Shares of BioLine RX Ltd. soared 47% on heavy volume of 14.1 million shares in premarket trading Friday, after the Israel-based biopharmaceutical company announced positive interim results from a Phase 3 trial of motixafortide for stem cell mobilization (SCM) in multiple myeloma patients.

BioLine stock soars on heavy volume after 'compelling' results of cancer treatment trial

TEL AVIV, Israel, Oct. 30, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, today announced positive results from a planned interim analysis of the ongoing GENESIS Phase 3 trial of motixafortide for stem cell...

BioLineRx Announces Positive Results from Interim Analysis of GENESIS Phase 3 Trial of Motixafortide (BL-8040) in Stem Cell Mobilization

TEL AVIV, Israel, Oct. 29, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical Company focused on oncology, today announced that the Company's lead drug candidate, the CXCR4-inhibitor Motixafortide, will be tested in combination with the...

BioLineRx Announces Initiation of Phase 2 Clinical Trial in First-Line Metastatic Pancreatic Cancer

TEL AVIV, Israel, Aug. 19, 2020 /PRNewswire/ -- BioLineRx Ltd.

BioLineRx Achieves Enrollment Target in Phase 3 GENESIS Trial for Planned Interim Analysis

BioLine RX Ltd (BLRX) CEO Philip Serlin on Q2 2020 Results - Earnings Call Transcript

News for Bioline RX Stock (BLRX)